In This Section      
Print This Page

Promise and Progress - For Cervical Lesions, Tissue Exam Beats Conventional Blood Tests

Reprogramming Cancer Cells - The Story of Epigenetics
Issue No. 1

For Cervical Lesions, Tissue Exam Beats Conventional Blood Tests

Date: July 16, 2014

Science Translational Medicine, January 2014

An early clinical study showed that a vaccine used to treat women with high-grade precancerous cervical lesions causes an immune cell response within the precancerous cervical cells.  The study found that measuring immune system responses in the cervical lesions identified immune responses that were not detectable in the blood. Tissue immune biomarkers could more accurately evaluate if the therapeutic vaccine is working.  The study led by Kimmel Cancer Center cervical cancer expert, Cornelia Trimble, M.D., involved 12 patients who received vaccine therapy for a common type of cervical precancers.  Examination of cervical tissue showed more accurate pre- and post-vaccination response than blood samples.

Funding for the research and clinical trials was provided by the National Institutes of Health’s National Cancer Institute grants CA 123876, CA 14269101, CA098252, and CA0006973, and the Dana Foundation.

Find Physicians Specializing In...